Twist Bioscience Corporation
NASDAQ:TWSTMedical - Diagnostics & Research
+$2.15 today
- Market cap
- $7.66B
- Beta
- 2.21
- P/E (TTM)
- -64.5
- EPS (TTM)
- -$1.32
Volume 2.23M
Average 1.53M
TWST EBITDA Margin
EBITDA as a percentage of revenue.
Twist Bioscience CorporationNASDAQ: TWST
EBITDA Margin · Q4 FY2026 · quarter ended Sep 2026
EBITDA Margin narrows to -33.9%
EBITDA Margin was -33.9% in Q4 FY2026, down 12.8 pp from a year earlier. On a trailing-twelve-month basis it was -28.3%, down 14.5 pp year over year. Over 3 fiscal years it widened by 42.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 8 analysts of -7.1% for the fiscal year ending Sep 2027, up from -28.3% in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -33.9%-10.2 pp QoQ
- Last fiscal yearSep 2026
- -28.3%-14.4 pp YoY
- LTMSep 2026
- -28.3%-14.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -12.8 pp | +9.2 pp | +22.0 pp |
| 1 year | -14.4 pp | +21.1 pp | +35.5 pp |
| 3 years | +42.8 pp | +36.9 pp | -5.9 pp |
| 5 years | +51.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2026
- -28.3%
- Year-over-year change
- -14.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | -28.3% | -14.4pp |
| FY2025 | 2025-09-30 | -13.8% | +42.6pp |
| FY2024 | 2024-09-30 | -56.5% | +14.6pp |
| FY2023 | 2023-09-30 | -71.1% | +32.9pp |
| FY2022 | 2022-09-30 | -104.0% | — |
EBITDA Margin vs competitors
How TWST compares with its peers on the latest reported figures
- TWST's LTM Sep 2026 EBITDA Margin of -28.3% is the lowest of the 2 companies compared; the peer median is 22.3%.
- Its year-over-year change of -14.5 pp is the lowest of 2, against a peer median of +5.6 pp.
- Over three fiscal years its change of +42.8 pp compares with a peer median of -9.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 22.3% | +5.6 pp | -9.9 pp | |
| LTM Sep 2026 | -28.3% | -14.5 pp | +42.8 pp | |
| Peer median (excluding TWST) | 22.3% | +5.6 pp | -9.9 pp | |
Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 203.57M | 245.11M | 312.97M | 376.57M | 459.43M |
| Cost of Revenue | 119.33M | 155.38M | 179.63M | 185.57M | 218.63M |
| Gross Profit | 84.24M | 89.73M | 133.35M | 191M | 240.8M |
| Gross Margin | 41.4% | 36.6% | 42.6% | 50.7% | 52.4% |
| Research & Development | 120.31M | 106.89M | 90.85M | 80.29M | 71.84M |
| Selling, General & Admin | 212.95M | 189.74M | 218.4M | 246.98M | 301.22M |
| Operating Expenses | 319.01M | 306.89M | 354.18M | 327.26M | 380.26M |
| Depreciation & Amortization | 16.51M | 29.31M | 31.43M | 24.85M | 0 |
| EBITDA | (211.68M) | (174.15M) | (176.71M) | (52.1M) | (129.8M) |
| EBITDA Margin | -104.0% | -71.1% | -56.5% | -13.8% | -28.3% |
| Operating Income | (234.78M) | (217.16M) | (220.83M) | (136.26M) | (139.46M) |
| Operating Margin | -115.3% | -88.6% | -70.6% | -36.2% | -30.4% |
| Interest Income | 3.06M | 14.37M | 15.34M | 11.36M | 8.8M |
| Interest Expense | 80K | 5K | 29K | 0 | 0 |
| Other Income / Expenses | 6.5M | 13.69M | 12.67M | 59.31M | 8.85M |
| Income Before Tax | (228.27M) | (203.47M) | (208.17M) | (76.95M) | (130.61M) |
| Pre-Tax Margin | -112.1% | -83.0% | -66.5% | -20.4% | -28.4% |
| Income Tax Expense | (10.41M) | 1.15M | 560K | 719K | (406K) |
| Net Income | (217.86M) | (204.62M) | (208.73M) | (77.67M) | (130.2M) |
| Net Margin | -107.0% | -83.5% | -66.7% | -20.6% | -28.3% |
| EPS (Basic) | (4.04) | (3.60) | (3.60) | (1.30) | (2.08) |
| EPS (Diluted) | (4.04) | (3.60) | (3.60) | (1.30) | (2.08) |
| Weighted Avg Shares | 53.89M | 56.89M | 58.02M | 59.81M | 62.62M |
| Weighted Avg Shares (Diluted) | 53.89M | 56.89M | 58.02M | 59.81M | 62.62M |
Twist Bioscience Corporation
NASDAQ:TWST
Intrinsic Alpha fair value
Locked
Current Price
$116.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.